Rivaroxaban and Aspirin Dual Therapy for Peripheral Artery Disease
A meta-analysis of COMPASS and VOYAGER compared low-dose rivaroxaban and aspirin vs aspirin alone across a broad spectrum of patients with PAD.
A meta-analysis of COMPASS and VOYAGER compared low-dose rivaroxaban and aspirin vs aspirin alone across a broad spectrum of patients with PAD.
A prospective, cross-sectional study examined the relationship between symptomatic and asymptomatic PAD with risk for abdominal aortic aneurysm.
Investigators evaluated outcomes of a first-line hybrid approach in patients with chronic limb-threatening ischemia to determine possible predictors of loss of primary patency and limb clinical improvement.
The approval was based on data from the phase 3 VOYAGER PAD study.
This review examines the current guidance and issues related to lipid optimization of patients with peripheral arterial disease (PAD).
The researchers’ goal was to determine the clinical impact of stent graft thrombosis and its prognosis.
Researchers found an additive benefit with rivaroxaban in combination with aspirin in terms of event reduction.
Researchers report the results of a systematic review assessing risk factors for peripheral artery disease in populations with type 2 diabetes.
SAFE-PAD evaluated the real-world safety of femoropopliteal artery revascularization using drug-coated vs non-drug-coated devices.
Investigators sought to determine whether elevated E/e’ ratio is an independent predictor for mortality at 5 years among patients undergoing percutaneous transluminal angioplasty for peripheral artery disease.